Review: Chemoprevention of esophageal adenocarcinoma

Therapeutic Advances in Gastroenterology

Volumn 1, Issue 1, 2008, Pages 7-18

  Abrams, Julian A ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

adenocarcinoma; chemoprevention; esophageal cancer

Indexed keywords

EID: 84993728235     PISSN: 1756283X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756283X08093568     Document Type: Review

References (123)

1. Abdalla, S.I., Lao-Sirieix, P., Novelli, M.R., Lovat, L.B., Sanderson, I.R. and Fitzgerald, R.C. (2004) Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis. Clin Cancer Res 10: 4784-4792.
2. Abdalla, S.I., Sanderson, I.R. and Fitzgerald, R.C. (2005) Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells. Carcinogenesis 26: 1627-1633.
3. Anderson, L.A., Johnston, B.T., Watson, R.G., Murphy, S.J., Ferguson, H.R., Comber, H. et al. (2006) Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res 66: 4975-4982.
4. Arber, N., Eagle, C.J., Spicak, J., Racz, I., Dite, P., Hajer, J. et al. (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355: 885-895.
5. Bardou, M., Barkun, A.N., Ghosn, J., Hudson, M. and Rahme, E. (2004) Effect of chronic intake of NSAIDs and cyclooxygenase 2-selective inhibitors on esophageal cancer incidence. Clin Gastroenterol Hepatol 2: 880-887.
6. Baron, J.A., Cole, B.F., Sandler, R.S., Haile, R.W., Ahnen, D., Bresalier, R. et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348: 891-899.
7. Baron, J.A., Sandler, R.S., Haile, R.W., Mandel, J.S., Mott, L.A. and Greenberg, E.R. (1998) Folate intake, alcohol consumption, cigarette smoking, and risk of colorectal adenomas. J Natl Cancer Inst 90: 57-62.
8. Bertagnolli, M.M., Eagle, C.J., Zauber, A.G., Redston, M., Solomon, S.D., Kim, K. et al. (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355: 873-884.
9. Buttar, N.S., Wang, K.K., Anderson, M.A., Dierkhising, R.A., Pacifico, R.J., Krishnadath, K.K. et al. (2002 a) The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst 94: 422-429.
10. Buttar, N.S., Wang, K.K., Leontovich, O., Westcott, J.Y., Pacifico, R.J., Anderson, M.A. et al. (2002 b) Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 122: 1101-1112.
11. Cabrera, C., Artacho, R. and Gimenez, R. (2006) Beneficial effects of green tea-a review. J Am Coll Nutr 25: 79-99.
12. Chandanos, E., Lindblad, M., Jia, C., Rubio, C.A., Ye, W. and Lagergren, J. (2006) Tamoxifen exposure and risk of oesophageal and gastric adenocarcinoma: a population-based cohort study of breast cancer patients in Sweden. Br J Cancer 95: 118-122.
13. Chang, C.L., Hong, E., Lao-Sirieix, P. and Fitzgerald, R.C. (2007 a) A novel role for the retinoic acid-catabolizing enzyme CYP26A1 in Barrett's associated adenocarcinoma. Oncogene (2008) 27: 2951-60.
14. Chang, C.L., Lao-Sirieix, P., Save, V., de La Cueva Mendez, G., Laskey, R. and Fitzgerald, R.C. (2007 b) Retinoic acid-induced glandular differentiation of the oesophagus. Gut 56: 906-917.
15. Chen, H., Tucker, K.L., Graubard, B.I., Heineman, E.F., Markin, R.S., Potischman, N.A. et al. (2002) Nutrient intakes and adenocarcinoma of the esophagus and distal stomach. Nutr Cancer 42: 33-40.
16. Chen, T., Hwang, H., Rose, M.E., Nines, R.G. and Stoner, G.D. (2006) Chemopreventive properties of black raspberries in N-nitrosomethylbenzylamineinduced rat esophageal tumorigenesis: down-regulation of cyclooxygenase-2, inducible nitric oxide synthase, and c-Jun. Cancer Res 66: 2853-2859.
17. Cheng, K.K., Sharp, L., McKinney, P.A., Logan, R.F., Chilvers, C.E., Cook-Mozaffari, P. et al. (2000) A case-control study of oesophageal adenocarcinoma in women: a preventable disease. Br J Cancer 83: 127-132.
18. Choi, S.W. and Mason J.B. (2000) Folate and carcinogenesis: an integrated scheme. J Nutr 130: 129-132.
19. Chow, W.H., Finkle, W.D., McLaughlin, J.K., Frankl, H., Ziel, H.K. and Fraumeni Jr, J.F. (1995) The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. Jama 274: 474-477.
20. Clemons, N.J., McColl, K.E. and Fitzgerald, R.C. (2007) Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. Gastroenterology 133: 1198-1209.
21. Cole, B.F., Baron, J.A., Sandler, R.S., Haile, R.W., Ahnen, D.J., Bresalier, R.S. et al. (2007) Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. Jama 297: 2351-2359.
22. Cooper, B.T., Chapman, W., Neumann, C.S. and Gearty, J.C. (2006) Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther 23: 727-733.
23. Corley, D.A., Kerlikowske, K., Verma, R. and Buffler, P. (2003) Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology 124: 47-56.
24. Corley, D.A., Levin, T.R., Habel, L.A., Weiss, N.S. and Buffler, P.A. (2002) Surveillance and survival in Barrett's adenocarcinomas: a population-based study. Gastroenterology 122: 633-640.
25. D'Alessandro, T., Prasain, J., Benton, M.R., Botting, N., Moore, R., Darley-Usmar, V. et al. (2003) Polyphenols, inflammatory response, and cancer prevention: chlorination of isoflavones by human neutrophils. J Nutr 133.
26. Duan, L., Wu, A.H., Sullivan-Halley, J. and Bernstein, L. (2008) Nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric adenocarcinomas in Los Angeles County. Cancer Epidemiol Biomarkers Prev 17: 126-134.
27. El-Serag, H.B., Aguirre, T.V., Davis, S., Kuebeler, M., Bhattacharyya, A. and Sampliner, R.E. (2004 a) Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol 99: 1877-1883.
28. El-Serag, H.B., Petersen, N.J., Carter, J., Graham, D.Y., Richardson, P., Genta, R.M. et al. (2004 b) Gastroesophageal reflux among different racial groups in the United States. Gastroenterology 126: 1692-1699.
29. Farhadi, A., Fields, J., Banan, A. and Keshavarzian, A. (2002) Reactive oxygen species: are they involved in the pathogenesis of GERD, Barrett's esophagus, and the latter's progression toward esophageal cancer? Am J Gastroenterol 97: 22-26.
30. Farrow, D.C., Vaughan, T.L., Hansten, P.D., Stanford, J.L., Risch, H.A., Gammon, M.D. et al. (1998) Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 7: 97-102.
31. Farrow, D.C., Vaughan, T.L., Sweeney, C., Gammon, M.D., Chow, W.H., Risch, H.A. et al. (2000) Gastroesophageal reflux disease, use of H 2 receptor antagonists, and risk of esophageal and gastric cancer. Cancer Causes Control 11: 231-238.
32. Fass, R., Quan, S.F., O'Connor, G.T., Ervin, A. and Iber, C. (2005) Predictors of heartburn during sleep in a large prospective cohort study. Chest 127: 1658-1666.
33. Feagins, L.A., Zhang, H.Y., Hormi-Carver, K., Quinones, M.H., Thomas, D., Zhang, X. et al. (2007) Acid has antiproliferative effects in nonneoplastic Barrett's epithelial cells. Am J Gastroenterol 102: 10-20.
34. Federico, A., Morgillo, F., Tuccillo, C., Ciardiello, F. and Loguercio, C. (2007) Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 121: 2381-2386.
35. Ferrario, C.M. and Strawn, W.B. (2006) Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 98: 121-128.
36. Fiorucci, S., Santucci, L., Farroni, F., Pelli, M.A. and Morelli, A. (1989) Effect of omeprazole on gastroesophageal reflux in Barrett's esophagus. Am J Gastroenterol 84: 1263-1267.
37. Fitzgerald, R.C., Omary, M.B. and Triadafilopoulos, G. (1996) Dynamic effects of acid on Barrett's esophagus. An ex vivo proliferation and differentiation model. J Clin Invest 98: 2120-2128.
38. Freedman, N.D., Park, Y., Subar, A.F., Hollenbeck, A.R., Leitzmann, M.F., Schatzkin, A. et al. (2007) Fruit and vegetable intake and esophageal cancer in a large prospective cohort study. Int J Cancer 121: 2753-2760.
39. Funkhouser, E.M. and Sharp, G.B. (1995) Aspirin and reduced risk of esophageal carcinoma. Cancer 76: 1116-1119.
40. Gammon, M.D., Terry, M.B., Arber, N., Chow, W.H., Risch, H.A., Vaughan, T.L. et al. (2004) Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study. Cancer Epidemiol Biomarkers Prev 13: 34-39.
41. Garcia Rodriguez, L.A., Lagergren, J. and Lindblad, M. (2006) Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut 55: 1538-1544.
42. Georgopoulos, S.D., Polymeros, D., Triantafyllou, K., Spiliadi, C., Mentis, A., Karamanolis, D.G. et al. (2006) Hypergastrinemia is associated with increased risk of distal colon adenomas. Digestion 74: 42-46.
43. Gillen, P., Keeling, P., Byrne, P.J. and Hennessy, T.P. (1987) Barrett's oesophagus: pH profile. Br J Surg 74: 774-776.
44. Giovannucci, E., Rimm, E.B., Ascherio, A., Stampfer, M.J., Colditz, G.A. and Willett, W.C. (1995) Alcohol, low-methionine-low-folate diets, and risk of colon cancer in men. J Natl Cancer Inst 87: 265-273.
45. Giovannucci, E., Stampfer, M.J., Colditz, G.A., Hunter, D.J., Fuchs, C., Rosner, B.A. et al. (1998) Multivitamin use, folate, and colon cancer in women in the Nurses' Health Study. Ann Intern Med 129: 517-524.
46. Gonzalez, C.A., Pera, G., Agudo, A., Bueno-de-Mesquita, H.B., Ceroti, M., Boeing, H. et al. (2006) Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). Int J Cancer 118: 2559-2566.
47. Haigh, C.R., Attwood, S.E., Thompson, D.G., Jankowski, J.A., Kirton, C.M., Pritchard, D.M. et al. (2003) Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK 2 receptor. Gastroenterology 124: 615-625.
48. Hao, Y., Sood, S., Triadafilopoulos, G., Kim, J.H., Wang, Z., Sahbaie, P. et al. (2007) Gene expression changes associated with Barrett's esophagus and Barrett's-associated adenocarcinoma cell lines after acid or bile salt exposure. BMC Gastroenterol 7 (24): 1-10.
49. Harris, J.C., Clarke, P.A., Awan, A., Jankowski, J. and Watson, S.A. (2004) An antiapoptotic role for gastrin and the gastrin/CCK-2 receptor in Barrett's esophagus. Cancer Res 64: 1915-1919.
50. Heath, E.I., Canto, M.I., Piantadosi, S., Montgomery, E., Weinstein, W.M., Herman, J.G. et al. (2007) Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst 99: 545-557.
51. Hermann, B., Li, Y., Ray, M.B., Wo, J.M. and Martin, R.C.II. (2005) Association of manganese superoxide dismutase expression with progression of carcinogenesis in Barrett esophagus. Arch Surg 140: 1204-1209.
52. Hillman, L.C., Chiragakis, L., Shadbolt, B., Kaye, G.L. and Clarke, A.C. (2004) Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus. Med J Aust 180: 387-391.
53. Hillman, L.C., Chiragakis, L., Shadbolt, B., Kaye, G.L. and Clarke, A.C. (2008) Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus. Aliment Pharmacol Ther 27: 321-326.
54. Hormi-Carver, K., Feagins, L.A., Spechler, S.J. and Souza, R.F. (2007) All trans-retinoic acid induces apoptosis via p 38 and caspase pathways in metaplastic Barrett's cells. Am J Physiol Gastrointest Liver Physiol 292: G18-G27.
55. Howe, L.R. and Dannenberg, A.J. (2002) A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin Oncol 29: 111-119.
56. Hur, C., Nishioka, N.S. and Gazelle, G.S. (2004) Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 96: 316-325.
57. Iijima, K., Grant, J., McElroy, K., Fyfe, V., Preston, T. and McColl, K.E. (2003) Novel mechanism of nitrosative stress from dietary nitrate with relevance to gastro-oesophageal junction cancers. Carcinogenesis 24: 1951-1960.
58. Jankowski, J. and Moayyedi, P. (2004) Re: Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. J Natl Cancer Inst 96: 885-887.
59. Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J. and Thun, M.J. (2007) Cancer statistics, 2007. CA Cancer J Clin 57: 43-66.
60. Katz, P.O., Koch, F.K., Ballard, E.D., Bagin, R.G., Gautille, T.C., Checani, G.C. et al. (2007) Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment Pharmacol Ther 25: 197-205.
61. Katz, P.O., Scheiman, J.M. and Barkun, A.N. (2006) Review article: acid-related disease-what are the unmet clinical needs? Aliment Pharmacol Ther 23 Suppl 2: 9-22.
62. Kaur, B.S., Khamnehei, N., Iravani, M., Namburu, S.S., Lin, O. and Triadafilopoulos, G. (2002) Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 123: 60-67.
63. Koop, H., Klein, M. and Arnold, R. (1990) Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Ther 4: 131-138.
64. Kresty, L.A., Frankel, W.L., Hammond, C.D., Baird, M.E., Mele, J.M., Stoner, G.D. et al. (2006) Transitioning from preclinical to clinical chemopreventive assessments of lyophilized black raspberries: interim results show berries modulate markers of oxidative stress in Barrett's esophagus patients. Nutr Cancer 54: 148-156.
65. Kristal, A.R., Blount, P.L., Schenk, J.M., Sanchez, C.A., Rabinovitch, P.S., Odze, R.D. et al. (2005) Low-fat, high fruit and vegetable diets and weight loss do not affect biomarkers of cellular proliferation in Barrett esophagus. Cancer Epidemiol Biomarkers Prev 14: 2377-2383.
66. Kubo, A. and Corley, D.A. (2002) Marked regional variation in adenocarcinomas of the esophagus and the gastric cardia in the United States. Cancer 95: 2096-2102.
67. Kumagai, H., Mukaisho, K., Sugihara, H., Miwa, K., Yamamoto, G. and Hattori, T. (2004) Thioproline inhibits development of esophageal adenocarcinoma induced by gastroduodenal reflux in rats. Carcinogenesis 25: 723-727.
68. Kusyk, C.J., McNiel, N.O. and Johnson, L.R. (1986) Stimulation of growth of a colon cancer cell line by gastrin. Am J Physiol 251: G597-G601.
69. Lagergren, J., Bergstrom, R., Lindgren, A. and Nyren, O. (1999 a) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340: 825-831.
70. Lagergren, J., Bergstrom, R. and Nyren, O. (1999 b) Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 130: 883-890.
71. Lagergren, J. and Jansson, C. (2005) Sex hormones and oesophageal adenocarcinoma: influence of childbearing? Br J Cancer 93: 859-861.
72. Lagergren, J. and Nyren, O. (1998) Do sex hormones play a role in the etiology of esophageal adenocarcinoma? A new hypothesis tested in a population-based cohort of prostate cancer patients. Cancer Epidemiol Biomarkers Prev 7: 913-915.
73. Lagergren, J., Viklund, P. and Jansson, C. (2006) Carbonated soft drinks and risk of esophageal adenocarcinoma: a population-based case-control study. J Natl Cancer Inst 98: 1158-1161.
74. Lao-Sirieix, P., Roy, A., Worrall, C., Vowler, S.L., Gardiner, S. and Fitzgerald, R.C. (2006) Effect of acid suppression on molecular predictors for esophageal cancer. Cancer Epidemiol Biomarkers Prev 15: 288-293.
75. Larsson, S.C., Giovannucci, E. and Wolk, A. (2005) A prospective study of dietary folate intake and risk of colorectal cancer: modification by caffeine intake and cigarette smoking. Cancer Epidemiol Biomarkers Prev 14: 740-743.
76. Larsson, S.C., Giovannucci, E. and Wolk, A. (2006) Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology 131: 1271-1283.
77. Lindblad, M., Garcia Rodriguez, L.A., Chandanos, E. and Lagergren, J. (2006) Hormone replacement therapy and risks of oesophageal and gastric adenocarcinomas. Br J Cancer 94: 136-141.
78. Lord, R.V., Tsai, P.I., Danenberg, K.D., Peters, J.H., de Meester, T.R., Tsao-Wei, D.D. et al. (2001) Retinoic acid receptor-alpha messenger RNA expression is increased and retinoic acid receptor-gamma expression is decreased in Barrett's intestinal metaplasia, dysplasia, adenocarcinoma sequence. Surgery 129: 267-276.
79. Martin, R.C., Liu, Q., Wo, J.M., Ray, M.B. and Li, Y. (2007) Chemoprevention of carcinogenic progression to esophageal adenocarcinoma by the manganese superoxide dismutase supplementation. Clin Cancer Res 13: 5176-5182.
80. Masuda, M., Suzui, M., Lim, J.T. and Weinstein, I.B. (2003) Epigallocatechin-3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin Cancer Res 9: 3486-3491.
81. Masuda, M., Suzui, M. and Weinstein, I.B. (2001) Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 7: 4220-4229.
82. Mayne, S.T., Risch, H.A., Dubrow, R., Chow, W.H., Gammon, M.D., Vaughan, T.L. et al. (2006) Carbonated soft drink consumption and risk of esophageal adenocarcinoma. J Natl Cancer Inst 98: 72-75.
83. Mayne, S.T., Risch, H.A., Dubrow, R., Chow, W.H., Gammon, M.D., Vaughan, T.L. et al. (2001) Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 10: 1055-1062.
84. Mehta, S., Boddy, A., Johnson, I.T. and Rhodes, M. (2006) Systematic review: Cyclo-oxygenase-2 in human oesophageal adenocarcinogenesis. Aliment Pharmacol Ther 24: 1321-1331.
85. Morgan, C., Alazawi, W., Sirieix, P., Freeman, T., Coleman, N. and Fitzgerald, R. (2004) In vitro acid exposure has a differential effect on apoptotic and proliferative pathways in a Barrett's adenocarcinoma cell line. Am J Gastroenterol 99: 218-224.
86. Morris, C.D., Armstrong, G.R., Bigley, G., Green, H. and Attwood, S.E. (2001) Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol 96: 990-996.
87. Omenn, G.S., Goodman, G.E., Thornquist, M.D., Balmes, J., Cullen, M.R., Glass, A. et al. (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334: 1150-1155.
88. Ouatu-Lascar, R., Fitzgerald, R.C. and Triadafilopoulos, G. (1999) Differentiation and proliferation in Barrett's esophagus and the effects of acid suppression. Gastroenterology 117: 327-335.
89. Piazuelo, E., Cebrian, C., Escartin, A., Jimenez, P., Soteras, F., Ortego, J. et al. (2005) Superoxide dismutase prevents development of adenocarcinoma in a rat model of Barrett's esophagus. World J Gastroenterol 11: 7436-7443.
90. Rex, D.K., Cummings, O.W., Shaw, M., Cumings, M.D., Wong, R.K., Vasudeva, R.S. et al. (2003) Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 125: 1670-1677.
91. Ronkainen, J., Aro, P., Storskrubb, T., Johansson, S.E., Lind, T., Bolling-Sternevald, E. et al. (2005) Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology 129: 1825-1831.
92. Saffari, Y. and Sadrzadeh, S.M. (2004) Green tea metabolite EGCG protects membranes against oxidative damage in vitro. Life Sci 74: 1513-1518.
93. Sandler, R.S., Halabi, S., Baron, J.A., Budinger, S., Paskett, E., Keresztes, R. et al. (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348: 883-890.
94. Sasaki, S., Miwa, K., Fujimura, T., Oba, M., Miyashita, T. and Kinami, S. (2007) Ingestion of thioproline suppresses rat esophageal adenocarcinogenesis caused by duodenogastroesophageal reflux. Oncol Rep 18: 1443-1449.
95. Schlansky, B., Dimarino Jr, A.J., Loren, D., Infantolino, A., Kowalski, T. and Cohen, S. (2006) A survey of oesophageal cancer: pathology, stage and clinical presentation. Aliment Pharmacol Ther 23: 587-593.
96. Shaheen, N. and Ransohoff, D.F. (2002) Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. Jama 287: 1972-1981.
97. Shirvani, V.N., Ouatu-Lascar, R., Kaur, B.S., Omary, M.B. and Triadafilopoulos, G. (2000) Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 118: 487-496.
98. Sihvo, E.I., Salminen, J.T., Rantanen, T.K., Ramo, O.J., Ahotupa, M., Farkkila, M. et al. (2002) Oxidative stress has a role in malignant transformation in Barrett's oesophagus. Int J Cancer 102: 551-555.
99. Sjoberg, T., Garcia Rodriguez, L.A. and Lindblad, M. (2007) Angiotensin-converting enzyme inhibitors and risk of esophageal and gastric cancer: a nested case-control study. Clin Gastroenterol Hepatol 5: 1160-1166e1.
100. Smith, J.P. and Solomon, T.E. (1988) Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer. Gastroenterology 95: 1541-1548.
101. Sobhani, I., Lehy, T., Laurent-Puig, P., Cadiot, G., Ruszniewski, P. and Mignon, M. (1993) Chronic endogenous hypergastrinemia in humans: evidence for a mitogenic effect on the colonic mucosa. Gastroenterology 105: 22-30.
102. Soler, M., Bosetti, C., Franceschi, S., Negri, E., Zambon, P., Talamini, R. et al. (2001) Fiber intake and the risk of oral, pharyngeal and esophageal cancer. Int J Cancer 91: 283-287.
103. Sonnenberg, A. and Fennerty, M.B. (2003) Medical decision analysis of chemoprevention against esophageal adenocarcinoma. Gastroenterology 124: 1758-1766.
104. Souza, R.F., Shewmake, K., Beer, D.G., Cryer, B. and Spechler, S.J. (2000) Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 60: 5767-5772.
105. Souza, R.F., Shewmake, K., Pearson, S., Sarosi Jr, G.A., Feagins, L.A., Ramirez, R.D. et al. (2004) Acid increases proliferation via ERK and p 38 MAPKmediated increases in cyclooxygenase-2 in Barrett's adenocarcinoma cells. Am J Physiol Gastrointest Liver Physiol 287: G743-G748.
106. Souza, R.F., Shewmake, K., Terada, L.S. and Spechler, S.J. (2002) Acid exposure activates the mitogen-activated protein kinase pathways in Barrett's esophagus. Gastroenterology 122: 299-307.
107. Spechler, S.J. (2002) Clinical practice. Barrett's Esophagus. N Engl J Med 346: 836-842.
108. Stoner, G.D., Wang, L.S., Zikri, N., Chen, T., Hecht, S.S., Huang, C. et al. (2007) Cancer prevention with freeze-dried berries and berry components. Semin Cancer Biol 17: 403-410.
109. Sun, C.L., Yuan, J.M., Koh, W.P. and Yu, M.C. (2006) Green tea, black tea and colorectal cancer risk: a meta-analysis of epidemiologic studies. Carcinogenesis 27: 1301-1309.
110. Sun, S.Y. and Lotan, R. (2002) Retinoids and their receptors in cancer development and chemoprevention. Crit Rev Oncol Hematol 41: 41-55.
111. Terry, P., Lagergren, J., Hansen, H., Wolk, A. and Nyren, O. (2001) Fruit and vegetable consumption in the prevention of oesophageal and cardia cancers. Eur J Cancer Prev 10: 365-369.
112. Terry, P., Lagergren, J., Ye, W., Nyren, O. and Wolk, A. (2000) Antioxidants and cancers of the esophagus and gastric cardia. Int J Cancer 87: 750-754.
113. Thorburn, C.M., Friedman, G.D., Dickinson, C.J., Vogelman, J.H., Orentreich, N. and Parsonnet, J. (1998) Gastrin and colorectal cancer: a prospective study. Gastroenterology 115: 275-280.
114. Tsuda, M. and Kurashima, Y. (1991) Nitrite-trapping capacity of thioproline in the human body. IARC Sci Publ 00: 123-128.
115. Umansky, M., Yasui, W., Hallak, A., Brill, S., Shapira, I., Halpern, Z. et al. (2001) Proton pump inhibitors reduce cell cycle abnormalities in Barrett's esophagus. Oncogene 20: 7987-7991.
116. Sandick, J.W., van Lanschot, J.J., Kuiken, B.W., Tytgat, G.N., Offerhaus, G.J. and Obertop, H. (1998) Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. Gut 43: 216-222.
117. Vaughan, T.L., Dong, L.M., Blount, P.L., Ayub, K., Odze, R.D., Sanchez, C.A. et al. (2005) Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol 6: 945-952.
118. Vizcaino, A.P., Moreno, V., Lambert, R. and Parkin, D.M. (2002) Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973-1995. Int J Cancer 99: 860-868.
119. Wilson, K.T., Fu, S., Ramanujam, K.S. and Meltzer, S.J. (1998) Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res 58: 2929-2934.
120. Wright, T.A., Gray, M.R., Morris, A.I., Gilmore, I.T., Ellis, A., Smart, H.L. et al. (1996) Cost effectiveness of detecting Barrett's cancer. Gut 39: 574-579.
121. Yang, G., Shu, X.O., Li, H., Chow, W.H., Ji, B.T., Zhang, X. et al. (2007) Prospective cohort study of green tea consumption and colorectal cancer risk in women. Cancer Epidemiol Biomarkers Prev 16: 1219-1223.
122. Zhang, F., Altorki, N.K., Wu, Y.C., Soslow, R.A., Subbaramaiah, K. and Dannenberg, A.J. (2001) Duodenal reflux induces cyclooxygenase-2 in the esophageal mucosa of rats: evidence for involvement of bile acids. Gastroenterology 121: 1391-1399.
123. Zhang, H.Y., Zhang, X., Hormi-Carver, K., Feagins, L.A., Spechler, S.J. and Souza, R.F. (2007) In non-neoplastic Barrett's epithelial cells, acid exerts early antiproliferative effects through activation of the Chk 2 pathway. Cancer Res 67: 8580-8587.